Anti-programmed Death Receptor 1 Blockade Induces Clinical Response in a Patient With Metastatic Collecting Duct Carcinoma.

[1]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[2]  T. Choueiri,et al.  Non-clear cell renal cell carcinoma, part 2: therapy. , 2015, Clinical advances in hematology & oncology : H&O.

[3]  A. Hakimi,et al.  Metastatic Non-Clear Cell Renal Cell Carcinoma: An Evidence Based Review of Current Treatment Strategies , 2015, Front. Oncol..

[4]  G. Freeman,et al.  PD-L1 expression in nonclear-cell renal cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Kapoor,et al.  Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. , 2013, Current oncology.

[6]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Huzarski,et al.  Survival in patients with rare subtypes of renal cell carcinoma , 2002, BJU international.

[8]  R. Figlin,et al.  Collecting duct renal cell carcinoma: clinical study of a rare tumor. , 2002, The Journal of urology.